Abstract
Objectives: There is an important need to evaluate therapeutic approaches for osteoarthritis (OA) in terms of cost-effectiveness as well as efficacy. Methods: The ESCEO expert working group met to discuss the epidemiological and economic evidence that justifies the increasing concern of the impact of this disease and reviewed the current state-of-the-art in health economic studies in this field. Results: OA is a debilitating disease; it is increasing in frequency and is associated with a substantial and growing burden on society, in terms of both burden of illness and cost of illness. Economic evaluations in this field are relatively rare, and those that do exist, show considerable heterogeneity of methodological approach (such as indicated population, comparator, decision context and perspective, time horizon, modeling and outcome measures used). This heterogeneity makes comparisons between studies problematic. Conclusions: Better adherence to guidelines for economic evaluations is needed. There was strong support for the definition of a reference case and for what might constitute "standard optimal care" in terms of best clinical practice, for the control arms of interventional studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 303-313 |
| Number of pages | 11 |
| Journal | Seminars in Arthritis and Rheumatism |
| Volume | 43 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 2013 |
Funding
M.H. (Mickael Hiligsmann) has received research grant, lecture fees, and/or consulting fees from Amgen, Pfizer, Novartis, Servier, and SMB. C.C. has received honoraria and consulting fees from AMGEN, GSK, Alliance for Better Bone Health, MSD, Eli Lilly, Pfizer, Novartis, Servier, Medtronic, and Roche. M.-L.B. was consultant and grant recipient from Amgen, Eli Lilly, MSD, Novartis, NPS, Roche, and Servier. O.B. has received grant research from IBSA, Merck Sharp & Dohme, Nutraveris, Novartis, Pfizer, Rottapharm, Servier, and Theramex; consulting or lecture fees from IBSA, Rottapharm, Servier, and SMB; and reimbursement for attending meetings from IBSA, Merck Sharp & Dohme, Novartis, Pfizer, Rottapharm, Servier, and Theramex. M.H. (Marc Hochberg) was a member of the Scientific Advisory Board of TREAT-OA Consortium; has served as a consultant to Abbott Laboratories, Allergan, Bioiberica S.A., Covidien, Iroko Pharmaceuticals, Merck & Co., and Pfizer Inc; and received speaker fees from Bioiberica S.A. and IBSA. D.H. receives royalties from DJO. T.K. has received fees for speaking from Abbott, AstraZeneka, Hospira, MSD/Schering-Plough, Nicox, Pfizer/Wyeth, Roche, and UCB; funds for research from Diakonhjemmet Hospital from Abbott, BMS, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB; and fees for consulting from Abbott, BMS, MSD/Schering-Plough, Nicox, Pfizer/Wyeth, Roche, and UCB. S.S. has served as an advisor for Lilly, Novartis, and Pfizer/Wyeth; has served as a consultant for Genentech, Lilly, Novartis, and Pfizer/Wyeth; and has received research support from Lilly and Pfizer/Wyeth. R.R. has received consulting and lecture fees for Merck Sharp and Dohme, Eli Lilly, Amgen, Novartis, Servier, Nycomed, Nestlé, and Danone. L.R. is an employee of Rottapharm. Y.T. is an employee of Servier. P.T. has received from UCB, Chelsea, and BMS. J.-Y.R. has received consulting fees, paid advisory boards, lecture fees, and/or grant support from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB, Merck Sharp and Dohme, Rottapharm, IBSA, Genevrier, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Novo-Nordisk, and Bristol Myers Squibb.
Keywords
- Arthroplasty
- Cost-effectiveness
- Cost-utility
- Economics
- Methods
- Osteoarthritis
- Review
ASJC Scopus subject areas
- Rheumatology
- Anesthesiology and Pain Medicine